The present invention provides compounds of the formula (I)

##STR00001## wherein: X.sub.1, X.sub.2 and X.sub.3 are heteroatoms; R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.3, R.sub.9 and R.sub.10 are independently selected from H, halo, —OH, —NO.sub.2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C.sub.1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR.sup.1—, —C(O)NR.sup.1NR.sup.2—, —C(O)O—, —OC(O)—, —NR.sup.1CO.sub.2—, —O—, —NR.sup.1C(O)NR.sup.2—, —OC(O)NR.sup.1—, —NR.sup.1NR.sup.2—, —NR.sup.1C(O)—, —S—, —SO—, —SO.sub.2—, —NR.sup.1—, —SO.sub.2NR.sup.1—, —NR.sup.1R.sup.2, or —NR.sup.1SO.sub.2—, wherein R.sup.1 and R.sup.2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR.sup.1R.sup.2, R.sup.1 and R.sup.2 optionally together with the nitrogen atom form an optionally substituted 5-12 membered ring, said ring optionally comprising 1 or more heteroatoms or a group selected from —CO—, —SO—, —SO.sub.2— and —PO—; or a pharmaceutically acceptable salt, ester or prodrug thereof.

The present disclosure relates to a 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof, in combination with at least one serotonergic agent or a derivative, precursor or metabolite thereof for use in the prevention and/or treatment of premature ejaculation, wherein the 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof is administered separately, sequentially or simultaneously to the at least one serotonergic agent or a derivative, precursor or metabolite thereof.

The present disclosure relates to a 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof, in combination with at least one serotonergic agent or a derivative, precursor or metabolite thereof for use in the prevention and/or treatment of premature ejaculation, wherein the 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof is administered separately, sequentially or simultaneously to the at least one serotonergic agent or a derivative, precursor or metabolite thereof.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Provided in the present invention are uses of duloxetine hydrochloride in preparing a pharmaceutical composition for treatment of cancer.

A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.

A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.

This invention is in the field of medicinal chemistry. In particular, the invention relates to mixed disulfide conjugates of thienopyridine compounds, and their use as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases.

This invention is in the field of medicinal chemistry. In particular, the invention relates to mixed disulfide conjugates of thienopyridine compounds, and their use as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases.